Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/6/2026 | $7.00 → $9.00 | Buy | H.C. Wainwright |
4 - NovaBridge Biosciences (0001778016) (Issuer)
4 - NovaBridge Biosciences (0001778016) (Issuer)
4 - NovaBridge Biosciences (0001778016) (Issuer)
6-K - NovaBridge Biosciences (0001778016) (Filer)
6-K - NovaBridge Biosciences (0001778016) (Filer)
20-F - NovaBridge Biosciences (0001778016) (Filer)
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company's senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026. Conference details are as follows: 2026 Jefferies Global Healthcare ConferenceFormat: Company Presentation and one-on-one investor meetingsDate: Thursday, June 4, 2026Presentation time: 3:10 PM ET Webcast Link: Here The webcast of the Jefferies presentation will be accessible on th
ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of NovaBridge's management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference being held on May 19, 2026. Conference details are as follows: H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat Date: Tuesday, May 19, 2026Time: 3:30 PM ETWebcast Link: Here The webcast of the company presentation will be accessible on the News & Events page of th
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmologyStrengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific antibody for first line (1L) gastric cancer, toward registrational pivotal studies and continues to advance VIS-101, purpose-designed, potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- NovaBridge Bioscienc
H.C. Wainwright resumed coverage of NovaBridge Biosciences with a rating of Buy and set a new price target of $9.00 from $7.00 previously
4 - NovaBridge Biosciences (0001778016) (Issuer)
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmologyStrengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific antibody for first line (1L) gastric cancer, toward registrational pivotal studies and continues to advance VIS-101, purpose-designed, potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- NovaBridge Bioscienc
Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA's Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026VIS-101, a potential best-in-class VEGF-A X ANG-2 inhibitor for wet-AMD, produced rapid, robust and durable responses in treatment naïve wet-AMD patients, and is poi
Appointment is a positive endorsement of NovaBridge's unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge's mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge subsidiary company Visara, Inc., will also join the Board's Research and Development Committee, established to expedite innovation and long-term growth ROCKVILLE, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or t
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMDVIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mmPotentially best-in-class durability with a favorable safety profile and no dose-limiting toxicityPhase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027Conference Call and Webcast today, March 09 at 9:00 AM ET ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or t